Sirio Pharma hires Sara Lesina as new general manager in Europe
Lesina was previously with Lonza as executive director and will be responsible for implementing a strategy that targets small and medium brands launching novel nutraceutical formulations.
Sara Lesina. Image courtesy of Sirio Pharma.
Sirio Pharma (Pritzwalk, Germany) appointed Sara Lesina as general manager in Europe. Lesina was previously with Lonza as executive director and will be responsible for implementing a strategy that targets small and medium brands launching novel nutraceutical formulations.
“I joined Sirio because I see the tremendous resources it has—over 200 R&D scientists across its sites—and there are clear synergies with like-minded innovation focused customers,” saidLesina in a press release. “We anticipate significant growth in the nutra market in next few years as customers see the benefits of working with an agile CDMO partner to help launch products to market faster. The Sirio value proposition anchored on R&D and formulation capabilities, combined with our global manufacturing footprint, positions us well to tap into this growth by launching new products for customers.”
Rui Yang, vice president at Sirio Pharma, said in a press release: “Sara brings with her a tremendous global network and what impressed us is the clarity of purpose to establish Sirio as the contract research and development hub for the most ambitious global brands. Across Europe there is an increasing number of companies launching new products that could reduce their time to market and/or acquisition by working with Sirio. Sara’s remit will be to help develop locally relevant formulatory options, working as the European conduit to access Sirio’s global R&D resources.”
FDA revokes authorization to use Red No. 3 as a color additive in food or drugs
January 15th 2025FDA contends that the color additive is safe for humans but is legally obligated by the Delaney Clause of the FD&C act to revoke authorization as research shows the Red No. 3 induces cancer in rats.
